Why the study?
Does intravenous ganciclovir improve cardiac muscle contractility in an immunocompetent infant with cytomegalovirus myocarditis?
Does intravenous ganciclovir improve cardiac muscle contractility in an immunocompetent infant with cytomegalovirus myocarditis?
Intravenous ganciclovir may be an effective treatment for acute cytomegalovirus myocarditis even in immunocompetent infants.
Answers are grounded in this paper and cite their sources.
May support ganciclovir in CMV myocarditis; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dehtiar et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: